4//SEC Filing
Quinlan Paul T 4
Accession 0001062993-24-000923
CIK 0001042074other
Filed
Jan 15, 7:00 PM ET
Accepted
Jan 16, 7:07 PM ET
Size
9.0 KB
Accession
0001062993-24-000923
Insider Transaction Report
Form 4
Quinlan Paul T
General Counsel
Transactions
- Exercise/Conversion
Employee Stock Option (right to buy)
2024-01-16−5,000→ 107,000 totalExercise: $2.94Exp: 2032-01-24→ Common Stock (5,000 underlying) - Sale
Common Stock
2024-01-16$23.58/sh−5,000$117,898→ 0 total - Exercise/Conversion
Common Stock
2024-01-16$2.94/sh+5,000$14,700→ 5,000 total
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.48 to $23.70, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2022.
Issuer
CymaBay Therapeutics, Inc.
CIK 0001042074
Entity typeother
Related Parties
1- filerCIK 0001333277
Filing Metadata
- Form type
- 4
- Filed
- Jan 15, 7:00 PM ET
- Accepted
- Jan 16, 7:07 PM ET
- Size
- 9.0 KB